Modification of the 8 AJCC staging system of pancreatic ductal adenocarcinoma.
作者信息
Nagaria Teddy Sutardji, Wang Huamin
机构信息
Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Hepatobiliary Surg Nutr. 2020 Feb;9(1):95-97. doi: 10.21037/hbsn.2019.08.01.
Abstract
摘要
相似文献
1
Modification of the 8 AJCC staging system of pancreatic ductal adenocarcinoma.胰腺导管腺癌美国癌症联合委员会（AJCC）第8版分期系统的修订
Hepatobiliary Surg Nutr. 2020 Feb;9(1):95-97. doi: 10.21037/hbsn.2019.08.01.
2
Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8 edition of the American Joint Committee on Cancer staging system.肠系膜门静脉侵犯应成为胰腺导管腺癌 TNM 分期的一个重要因素：美国癌症联合委员会第 8 版分期系统的修改建议。
World J Gastroenterol. 2019 Dec 14;25(46):6752-6766. doi: 10.3748/wjg.v25.i46.6752.
3
Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis.使用递归划分分析优化美国癌症联合委员会可切除胰腺导管腺癌分期方案
J Cancer. 2017 Aug 23;8(14):2765-2773. doi: 10.7150/jca.19515. eCollection 2017.
4
Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma.第八版 AJCC 胰腺癌分期系统的修改建议。
Ann Surg. 2019 May;269(5):944-950. doi: 10.1097/SLA.0000000000002668.
5
White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.美国腹部放射学会胰腺导管腺癌疾病聚焦专家组关于胰腺导管腺癌的白皮书：第一部分，AJCC 分期系统、NCCN 指南和交界可切除疾病。
Abdom Radiol (NY). 2020 Mar;45(3):716-728. doi: 10.1007/s00261-019-02289-5.
6
Validation of American Joint Committee on Cancer 8 edition of TNM staging in resected distal pancreatic cancer.美国癌症联合委员会第8版TNM分期在可切除性远端胰腺癌中的验证
World J Gastrointest Pharmacol Ther. 2020 Jun 9;11(2):25-39. doi: 10.4292/wjgpt.v11.i2.25.
7
Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma.优化第八版 AJCC TNM 分期系统用于可切除胰腺导管腺癌。
Future Oncol. 2019 Oct;15(30):3457-3465. doi: 10.2217/fon-2019-0264. Epub 2019 Aug 28.
8
Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis.为美国癌症联合委员会可切除胰腺导管腺癌分期配备肿瘤分级：递归划分分析
Med Oncol. 2016 Nov;33(11):122. doi: 10.1007/s12032-016-0839-4. Epub 2016 Oct 11.
9
Assessment of the external validity of the AJCC 8 staging system for small intestinal adenocarcinoma: a time to reconsider the role of tumor location?美国癌症联合委员会（AJCC）第8版小肠腺癌分期系统的外部有效性评估：是时候重新审视肿瘤位置的作用了吗？
J Gastrointest Oncol. 2019 Jun;10(3):421-428. doi: 10.21037/jgo.2019.01.15.
10
Proposal of a modified American Joint Committee on Cancer staging scheme for resectable pancreatic ductal adenocarcinoma with a lymph node ratio-based N classification: A retrospective cohort study.基于淋巴结比率的N分类对可切除胰腺导管腺癌的改良美国癌症联合委员会分期方案的提议：一项回顾性队列研究
Medicine (Baltimore). 2018 Aug;97(34):e12094. doi: 10.1097/MD.0000000000012094.
引用本文的文献
1
Long non-coding RNA MIR4435-2HG promotes pancreatic cancer progression by regulating ABHD17C through sponging miR-128-3p.长链非编码RNA MIR4435-2HG通过海绵吸附miR-128-3p调控ABHD17C促进胰腺癌进展。
Transl Cancer Res. 2024 Aug 31;13(8):4113-4130. doi: 10.21037/tcr-24-51. Epub 2024 Aug 23.
2
MR Molecular Image Guided Treatment of Pancreatic Cancer with Targeted ECO/miR-200c Nanoparticles in Immunocompetent Mouse Tumor Models.MR 分子影像引导的针对免疫活性小鼠肿瘤模型中 ECO/miR-200c 纳米颗粒的靶向治疗胰腺癌。
Pharm Res. 2024 Sep;41(9):1811-1825. doi: 10.1007/s11095-024-03762-7. Epub 2024 Aug 28.
3
Levels of retinol and retinoic acid in pancreatic cancer, type-2 diabetes and chronic pancreatitis.胰腺癌、2 型糖尿病和慢性胰腺炎中的视黄醇和视黄酸水平。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024 Jun;168(2):132-138. doi: 10.5507/bp.2023.049. Epub 2023 Dec 6.
4
Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy.接受新辅助FOLFIRINOX或吉西他滨/纳米白蛋白结合型紫杉醇治疗及胰腺切除术的胰腺导管腺癌患者的预后因素
Cancers (Basel). 2023 May 4;15(9):2608. doi: 10.3390/cancers15092608.
5
New nomogram for predicting lymph node positivity in pancreatic head cancer.预测胰头癌淋巴结阳性的新列线图。
Front Oncol. 2023 Jan 25;13:1053375. doi: 10.3389/fonc.2023.1053375. eCollection 2023.
6
Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.新辅助治疗后切除的胰腺导管腺癌病理评估中的关键问题：叙述性综述。
Chin Clin Oncol. 2022 Jun;11(3):21. doi: 10.21037/cco-21-175. Epub 2022 Jun 16.
7
Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society.经治疗的胰腺导管腺癌切除标本的病理学检查：来自肝胆胰病理学学会的建议
Am J Surg Pathol. 2022 Jun 1;46(6):754-764. doi: 10.1097/PAS.0000000000001853. Epub 2021 Dec 15.
8
Case report: identification of fusion in a patient with pancreatic ductal adenocarcinoma.病例报告：一名胰腺导管腺癌患者中融合基因的鉴定。
Gland Surg. 2021 Sep;10(9):2874-2879. doi: 10.21037/gs-21-469.
9
Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.胰腺导管腺癌治疗后肿瘤大小和体积的影像学测量与临床病理相关性分析。
Pancreatology. 2021 Jan;21(1):200-207. doi: 10.1016/j.pan.2020.11.003. Epub 2020 Nov 14.
本文引用的文献
1
Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma.第八版 AJCC 胰腺癌分期系统的修改建议。
Ann Surg. 2019 May;269(5):944-950. doi: 10.1097/SLA.0000000000002668.
2
Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.新AJCC肿瘤分期对接受新辅助治疗的胰腺导管腺癌患者的预后意义
Am J Surg Pathol. 2017 Aug;41(8):1097-1104. doi: 10.1097/PAS.0000000000000887.
3
Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.美国国立综合癌症网络（第8版）对胰腺腺癌患者T和N分期改变的多机构验证研究
Ann Surg. 2017 Jan;265(1):185-191. doi: 10.1097/SLA.0000000000001763.
4
Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.在大多数接受切除的病例中，胰腺导管腺癌已扩散至胰腺周围软组织，这使得美国癌症联合委员会（AJCC）的T分期方案（第7版）不再适用且意义不大：基于大小的分期系统（pT1：≤2cm，pT2：>2cm-≤4cm，pT3：>4cm）更有效且与临床相关。
Ann Surg Oncol. 2016 Jun;23(6):2010-8. doi: 10.1245/s10434-016-5093-7. Epub 2016 Jan 29.
5
Number of examined lymph nodes and nodal status assessment in pancreaticoduodenectomy for pancreatic adenocarcinoma.胰头十二指肠切除术治疗胰腺腺癌时的检查淋巴结数量和淋巴结状态评估。
Eur J Surg Oncol. 2013 Oct;39(10):1116-21. doi: 10.1016/j.ejso.2013.07.089. Epub 2013 Aug 12.
6
Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma.评估的淋巴结数量：胰腺腺癌的预后价值。
J Gastrointest Surg. 2012 May;16(5):920-6. doi: 10.1007/s11605-012-1853-2. Epub 2012 Mar 16.
7
Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.新辅助放化疗治疗胰导管腺癌患者的治疗后病理分期和生存。
Cancer. 2012 Jan 1;118(1):268-77. doi: 10.1002/cncr.26243. Epub 2011 Jul 6.
Zotero 插件